Index L
- Labetalol 843t
- Laboratory values 1383-1385, 1384t (see also specific tests)
- Lacrimal gland
- age-related changes in 1288-1289
-Lactamase inhibitors 1368t
- Lactase deficiency 1088
- Lactose-hydrogen breath test 1090
- Lacunar infarcts 367, 411-413, 412t
- Langerhans' cells 1236
- Language
- age-related changes in 380, 424-425
- assessment of 348-349, 424-425
- in dementia 358,
361t
- disorders of 424-428, 424t, 426t, 427t
- Lansoprazole 1046, 1047
- Laparotomy
- in Crohn's disease 1066
- in gastrointestinal tract bleeding 1108
- Laryngitis
- atrophic 1348-1349
- reflux 1349
- Laser therapy
- in photoaging 1238
- Latamoxel 1369t
- Latanoprost 1300t
- Lavage, nasogastric 1107
- Lawton Instrumental Activities of Daily Living Scale 43t, 45t
- Laxatives
- abuse of 1090
- in constipation 1084-1085, 1084t
- in diverticular disease 1055t
- in dying patient 119
- Lebetalol
- in hypertension 841t
- Leflunomide, in rheumatoid arthritis 502
- Left bundle branch block 895t, 899-900 (see also Arrhythmias)
- Left ventricular filling rate 816, 817f
- Left ventricular hypertrophy, electrocardiography in 824-825
- Leg
- amputation of
- pain after 286
- phantom limb after 286-287
- prosthesis for 285-286
- rehabilitation after 284-287
- stump conditioning after 285-286
- fracture of 222-227
- muscle cramps in 533-535, 534f
- pain in28t
- stasis dermatitis of 1251-1252
- venous ulcers of 1252-1254
- Legal issues 127-141
- advance directives and 134-135
- assisted suicide and 139
- capacity and 128-130
- competence and 130-131
- doctrine of privilege and 133
- do-not-resuscitate orders and 138-139
- driving and 237
- durable power of attorney and 135
- dying patient and 123-125
- euthanasia and 139
- fluid withholding and 139
- hospital discharge and 140-141
- incompetence and 130-131
- informed consent and 131-133
- living will and 134-135
- long-term care and 141
- nutrition withholding and 139
- palliation and 140
- Patient's Bill of Rights and 129t
- resources on 1415
- surrogate decision making and 135-138
- therapeutic privilege and 133
- Legionella infection 759, 760, 762t
- Leiomyosarcoma
- colorectal 1141-1144
- small-intestine 1139-1140
- Lens
- age-related changes in 1287-1288
- opacities of 1290-1291, 1293-1295
- Lentigines 1236
- Lentigo maligna 1278
- Leptin 596
- Leriche's syndrome 916
- Letrozole 721t, 1226t
- Leukemia
- acute 724-728
- chronic 728-732, 731t
- hyperphosphatemia in 582
- lymphoblastic (lymphocytic)
- acute 724-728
- chronic 728-732, 731t, 1358
- myelocytic (myeloid, myeloblastic)
- acute 724-728
- chronic 728-732
- vs. primary thrombocythemia 707
- polycythemia vera conversion to 709
- Leukoplakia 1021
- Levobetaxolol 1300t
- Levobunolol 1300t
- Levodopa
- aging effect on 61t
- diuretic interaction with 69t
- dosage adjustments for 71
- in parkinsonism 437, 439-440
- sexual function and 1164t
- Levofloxacin 1372t
- Levorphanol 387t
- Levothyroxine sodium
- in hypothyroidism 646-647
- in thyroid nodules 654
- Lewy bodies 368
- dementia and 368
- Libido
- decrease in
- hormone-related 656t
- drug-induced 1163t, 1164t
- in men 1171-1174, 1172t
- in women 1176-1177
- Lice 1246t
- Lichen planus 1201
- Lichen sclerosus 1190, 1201
- Lichen simplex chronicus 1201, 1251
- Lidocaine 888t
- in benign oral disorders 1019
- infusion rate of 887
- during myocardial infarction 860
- in pain management 396
- in ventricular tachycardia 894
- Life-care communities 105t, 111-112, 171
- Life expectancy 11-12, 12t, 19t, 20-21
- active (disability-free) 21
- surgery and 240
- therapeutic objectives and 114
- Life span 4
- Lifestyle
- cardiovascular system aging and 822
- disease prevention and 51t
- modification of
- in coronary artery disease prevention 51t, 854
- in hypertension 51t, 838, 838t
- Light therapy
- in sleep disorders 454
- Likelihood ratio 1383
- Limbus 1286
- Lincomycin 1374t
- Lindane 1246t
- Linezolid 1367t
- Lipase deficiency 1088
- Lipids (see Cholesterol; Lipoproteins)
- Lipodermatosclerosis 1252
- Lipofuscin
- hepatic deposition of 1003
- in nerve cells 381
- Lipoma, colonic 1140-1141
- Lipoproteins
- age-related changes in 607
- in disease prevention 50t
- disorders of 606-624, 608t-609t, 610t
- atherosclerosis and 850
- classification of 607, 608t-609t
- dietary considerations in 613-616, 614t, 616t
- secondary 607, 610t, 611-612
- treatment of 612-624, 614t, 616t, 618t-620t
- measurement of 610-612, 612t
- Lips (see also Mouth)
- Lisinopril
- in hypertension 842t
- Lithium 320
- sexual function and 1164t
- Livedo reticularis 922
- Liver
- abscess of 1129-1130
- adenoma of 1148
- age-related changes in 1003-1005
- bleeding from 1111
- blood flow in 1005
- cancer of 1149-1150
- cysts of 1129
- disorders of 1070-1073, 1129-1130
- anemia with 678
- resource on 1415
- surgical outcome and 248
- drug-induced injury to 1375t
- drug metabolism by 57-59, 58t
- end-stage disease of 1071
- estrogen metabolism by 1213-1214, 1215
- focal nodular hyperplasia of 1148
- hemangioma of 1148-1149
- hepatitis of 1071-1072
- iron accumulation in 1072-1073
- peptic ulcer penetration of 1044
- regeneration of 1005
- testosterone toxicity to 1173
- transplantation of 1150
- tumors of 1143, 1148-1150
- Living alone 143-144
- Living arrangements 10, 11f
- Living will 134-135 (see also Legal issues)
- Lomefloxacin 1372t
- Longevity (see also Life expectancy) 4
- Long-term care 104-112, 105t (see also Nursing homes)
- legal issues of 141
- managed care and 162-163
- pharmacist in 85-86
- Loop diuretics
- in hypertension 839t
- Loperamide
- in diarrhea 1091t, 1092
- in fecal incontinence 1094
- in irritable bowel syndrome 1070
- Loracarbef 1370t
- Lorazepam
- adverse effects of 64t
- in agitation 356
- in generalized anxiety disorder 324
- Losartan
- in heart failure 907-908
- in hypertension 842t
- Lotion 1244t
- Lou Gehrig's disease (see Amyotrophic lateral sclerosis)
- Lovastatin 617, 618t, 621
- Low-air-loss bed 1269t
- Lp(a)
- elevated levels of 609t, 624
- measurement of 610
- Lubricants, vaginal 1159, 1178
- Lugol's solution 652
- Lumbar spine
- stenosis of 917-918
- traction for 277-278
- Lungs (see also at Pulmonary)
- age-related changes in 753-757
- biopsy of 798
- cancer of 800-806, 801t, 802t
- Eaton-Lambert syndrome in 522
- screening for 718t
- terminal 806
- treatment of 803-805, 803t, 804t
- chronic obstructive disease of 779-787, 783t
- (see also Chronic obstructive pulmonary disease)
- defense mechanisms of 757
- disease of (see also specific diseases)
- interstitial 793-799, 794t-796t
- resources on 1417
- surgical outcome and 247
- embolism to 771-778 (see also Pulmonary embolism)
- immune response of 757
- infection of 758-771, 762t
- nitrofurantoin-induced injury to 1374t
- in physical examination 34
- postoperative status of 252
- rales in 824
- rehabilitation therapy for 806-809
- Lung volume reduction surgery 786
- Lupus 503-505
- Lupus anticoagulant antibody 691, 921-922
- Luteinizing hormone (LH)
- age-related changes in 1172
- measurement of 1173
- Lyme disease
- dementia in 370
- Lymphangiectasia, intestinal 1100t, 1103
- Lymphangitic carcinomatosis
- pulmonary 796t
- Lymph nodes
- biopsy of, in Hodgkin's disease 744
- in breast cancer 1221-1222
- Lymphoblastic (lymphocytic) leukemia
- acute 724-728
- chronic 728-732, 731t
- Lymphocytes
- age-related changes in 673, 1352t, 1354-1356
- B 1352t, 1355-1356
- T 1352t, 1354-1355
- in HIV infection 1380, 1381
- thymic hormone effects on 1354
- Lymphocytic leukemia, chronic 1358
- Lymphoid system 673
- Lymphoma 742-752
- Burkitt's 748-749
- colorectal 1141-1144
- gastric 1137-1139
- Hodgkin's 743-747, 745t, 746t, 747t
- non-Hodgkin's 747-752, 748t, 749t, 752t
- pancreatic 1145
- small-intestine 1139-1140
|
 |
|
|
|